Avalon GloboCare Corp. (NASDAQ:ALBT) Sees Significant Decline in Short Interest

Avalon GloboCare Corp. (NASDAQ:ALBT) was the recipient of a significant decline in short interest in the month of December. As of December 31st, there was short interest totalling 22,400 shares, a decline of 80.4% from the December 15th total of 114,200 shares. Currently, 5.3% of the company’s shares are short sold. Based on an average daily volume of 1,430,000 shares, the short-interest ratio is currently 0.0 days.

Avalon GloboCare Stock Up 3.1 %

Shares of NASDAQ:ALBT opened at $3.35 on Wednesday. The business’s 50 day moving average is $3.34 and its 200 day moving average is $4.13. The stock has a market cap of $3.66 million, a P/E ratio of -0.17 and a beta of 0.19. Avalon GloboCare has a 52-week low of $2.11 and a 52-week high of $21.60.

About Avalon GloboCare

Avalon GloboCare Corp., together with its subsidiaries, owns and operates commercial real estate properties in the United States and China. The company develops and delivers transformative cellular therapeutics, precision diagnostics, and clinical laboratory services. Its leading candidates are AVA-001, an anti-CD19 CAR-T, which has completed first-in-human clinical trial for relapsed/refractory (R/R) B-cell lymphoblastic leukemia; and AVA-011 that has completed pre-clinical laboratory studies and undergoing IND-enabling process development stage to generate cGMP-grade AVA-011 CAR-T cells.